% | $
Quotes you view appear here for quick access.

Avanir Pharmaceuticals, Inc. Message Board

theefalcon 1 post  |  Last Activity: Sep 22, 2015 12:14 PM Member since: Nov 30, 2007
  • Reply to

    MS Multi Symptomatic Treatment Possibilities.

    by theefalcon Oct 26, 2011 6:02 AM
    theefalcon theefalcon Sep 22, 2015 12:14 PM Flag

    ALISO VIEJO, Calif., Sept. 22, 2015 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that results from a phase II study evaluating the efficacy and safety of AVP-923 for the treatment of agitation in patients with Alzheimer's disease were published today in the Journal of the American Medical Association (JAMA). The study showed that patients with moderate to severe agitation secondary to Alzheimer's disease who were treated with AVP-923 (a combination of dextromethorphan and quinidine) had a clinically meaningful and statistically significant improvement measured by the agitation/aggression domain of the Neuropsychiatric Inventory (NPI), compared with patients treated with placebo (p